TWA
KDNY

TCI Wealth Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

TCI Wealth Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-144
Closed -$3.33K – 2472
2023
Q1 		$3.33K Buy
+144
New +$3.43K ﹤0.01% 1791

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCI Wealth Advisors's KDNY Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 144 shares — an estimated $3.33K sold.

TCI Wealth Advisors first reported a position in KDNY in Q1 2023 and held it in 1 quarter. The position peaked at $3.33K in Q1 2023. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 144 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.33K.
  • TCI Wealth Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • TCI Wealth Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $3.33K in Q1 2023.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.